Research programme: COPD therapeutics - MitoRx Therapeutics
Latest Information Update: 28 Sep 2024
Price :
$50 *
At a glance
- Originator MitoRx Therapeutics
- Class Small molecules
- Mechanism of Action Electron transport chain complex protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Chronic obstructive pulmonary disease
Most Recent Events
- 12 Sep 2024 COPD therapeutics - MitoRx Therapeutics is available for licensing as of 12 Sep 2024. https://www.mitorxtherapeutics.com/#Contact
- 12 Sep 2024 Preclinical trials in Chronic obstructive pulmonary disease in United Kingdom (PO), prior to September 2024 (MitoRx Therapeutics pipeline, September 2024)